Subscribe to Search results

Scottish National Blood Transfusion Service directors agreed that a system acceptable to both to BTS England and Wales and to SNBTS should be evolved in relation to the supply of plasma from England to PFC.

Published on:

In his evidence to the Penrose Inquiry, Dr Foster reflected that the decision to build a large plant for England and Wales and not to send plasma to Scotland on the basis of costs could be seen as wrong.

Published on:

Dr Katharine Dormandy pursued home therapy with cryoprecipitate, but it had its limitations due to the freezing facilities required.

Published on:

Cryoprecipitate was a valuable and preferred therapeutical material.

Published on:

The PFC had very substantial spare fractionation capacity and would have been able to assist England and Wales.

Published on:

The Aberdeen North East Scotland Blood Transfusion Service explained that the plan to increase the use of plasmapheresis would involve an increase in the amount of donations collected from the centre.

Published on:

A study in Scotland compared machine and manual plasmapheresis and reported the benefits of machine plasmapheresis.

Published on:

The Liberton Unit would be capable of receiving 1,500 litres of plasma per week at its commissioning time and, if necessary, up to 3,000 litres of plasma per week.

Published on:

The Policy Steering Group agreed that BPL would process all plasma for England and Wales and the PFC would process plasma for Northern Ireland and Scotland.

Published on:

In a letter from M Draper to Thomas McLean, it was noted that although the programme to secure plasma for the production of Factor 8 blood products was underway, an increase in plasma supply was not anticipated for some months and the situation was to be kept under review.

Published on:

In a memo from Dr Archibald McIntyre to Dr Bell, concern was noted that the growth of plasmapheresis might deter donors.

Published on:

The SHHD asked the DHSS when the Protein Fractionation Centre would be provided with English plasma for fractionation.

Published on:

During the closing submissions made on behalf of the DHHS and NHSBT to the Inquiry, emphasis was placed on the constrained financial position of the UK during the 1970s.

Published on:

During the closing submissions made on behalf of the DHSC to the Inquiry, some reasons for the delay in achieving in self-sufficiency included the withdrawal of the Lister Institute from the running of BPL, the constraints of the site BPL occupied, and the time it took to purchase land from the Lister Institute to enable expansion.

Published on:

During the closing submissions made on behalf of the NHSBT to the Inquiry, emphasis was placed on the constrained financial position of the UK during the 1970s.

Published on:

In his written evidence to the Inquiry, Lord Norman Fowler noted that the overspend on the BPL project reflected "poorly on the Department".

Published on:

The delays and additional expenses incurred in the redevelopment of the BPL were caused by the complexity of the new plant site and build, the various re-designs which took place during the project, poor management from the CBLA, and a lack of close oversight by the DHSS.

Published on:

An incoming chief executive of the CBLA was reported to have told officials that on the basis of a lifetime's experience in the pharmaceutical industry the new BPL building represented value for money.

Published on:

Ministers invested money into the BPL project at a very considerable level despite the financial pressures on health spending at the time.

Published on:

In a memo from Gwen Watson to Strachan Heppell, it was noted that the BPL project had been "badly handled".

Published on: